After biosimilars launch, reference biologics’ list price increases stop and net costs fall. Currently, 7 reference biologics have at least 1 biosimilar competitor on the market, creating direct competition for those drugs.
Pharmaceutical Care
Management Association
325 7th Street, NW
Washington, DC 20004
Main: 202.756.5700
©2024 PCMA. All Rights Reserved.